Drugs / SIMOTAXEL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00277836 | — | neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00088647 | — | neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIMOTAXEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107372 ↗ |
| Known as | MST-997 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00088647 ↗ |
| Modality | Small molecule | “MST-997 is a taxane analog” NCT00277836 ↗ |
| Route | Intravenous | “Intravenous MST-997” NCT00088647 ↗ |